posting velocity //
Based on 9 events over 40 days. Green days had more opens than closes, red vice-versa. The dark line is the 7-day rolling average.
role mix //
The green layer is the current share of active openings by role. The grey dashed layer is the 90-day baseline — gaps between them show where the company is shifting its hiring mix.
seniority pyramid //
Seniority is not exposed by the source for this company.
Distribution of active openings by seniority. The 'unknown' row groups jobs from sources that don't expose seniority.
geography //
The source doesn't list a city for every role — 1 open roles across Israel.
View all roles →Active openings by region. Click a row to see jobs in that area.
time on market //
Median
13.2 days
25th pct
9.5 days
75th pct
15.4 days
Based on 4 closed jobs and 1 still open (right-censored). Curve is Kaplan-Meier; band is the 95% CI.Still collecting — median tracking age is ~13.2 days (need 14+). 0% of closures were within 3 days, which often reflects feed churn rather than hires.
Window: 180 days back. Don't read the mean — the long tail biases it. Median and percentiles are the honest summary.
Republish rate
—
Fewer than 10 closures in the window — not enough to compute.
ביזאבו מפטרת עוד 100 עובדים
Calcalist Tech ↗company intel · ai-generated
Updated 21d ago
In the Israeli market, the name "Cal" primarily refers to Cal - Israel Credit Cards Ltd., a financial institution that operates significant internal technology and data divisions. Founded in 1978, the company is headquartered in Givatayim and is held by Israel Discount Bank and the First International Bank of Israel (FIBI). If this refers to a distinct, pure-play technology startup by the same name, detailed public information is limited.
Cal issues and clears credit cards for international networks including Visa, Mastercard, and Diners Club in Israel. The company employs technology professionals in software engineering, data science, and cybersecurity. Its internal R&D efforts generally focus on consumer credit underwriting algorithms, risk management, and digital payment applications.
hiring signal · from our data
From our job data · always current
1 open roles in Israel
Live openings we track — Israel first, plus worldwide when we have them.
news feed
<p align="center"><i>First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.</i></p>
Jun 15, 2026
<p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p>
Jun 15, 2026
<p>Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application entitled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application was published under European publication number EP 4751737. The patent application covers Polyrizon’s proprietary <b>Trap & Target™ (T&T)</b> mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.</p>
Jun 10, 2026
<p>Jibril Rajoub tells ToI that those backing exiled ex-security chief Dahlan shouldn't be forced to sign 'humiliating' individual amnesty requests, as demanded by ruling Fatah party</p> <p>The post <a href="https://www.timesofisrael.com/in-rare-critique-senior-pa-official-says-abbass-exclusion-of-political-rivals-is-mistaken/">In rare critique, senior PA official says Abbas’s exclusion of political rivals is mistaken</a> appeared first on <a href="https://www.timesofisrael.com">The Times of Israel</a>.</p> <figure><img border="0" class="type:primaryImage" height="100" src="https://static-cdn.toi-media.com/www/uploads/2025/03/MYTACK-1024x640.jpg" title="In rare critique, senior PA official says Abbas’s exclusion of political rivals is mistaken" width="160" /></figure>
Jun 6, 2026
<p>PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease (HD) chorea<sup>3</sup> and the effect of AUSTEDO<sup>®</sup> or AUSTEDO XR<sup>®</sup> on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.<sup>1</sup><sup>,</sup><sup>2</sup> The data were presented at the Advanced Therapeutics in Movement & Related Disorders<sup>®</sup> Congress, held June 4 – 8, 2026, in Washington, DC.</p>
Jun 5, 2026